Interaction of the Anti-Inflammatory Annexin A1 Protein and Tacrolimus Immunosuppressant in the Renal Function of Rats

Autor(es)

Araujo, Leandro P. ^[1] ; Truzzi, Renata R. ^[2] ; Mendes, Gloria E. ^[3] ; Luz, Marcus A. M. ^[3] ; Burdmann, Emmanuel A. ^[3] ; Oliani, Sonia M. ^{[2, 1]}

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, Postgrad Program Morphol, Sao Paulo - Brazil

^[2] UNESP, IBILCE, Dept Biol, BR-15054000 Sao Jose Do Rio Preto, SP - Brazil

^[3] Sao Jose Rio Preto Med Sch, Div Nephrol, Sao Jose Do Rio Preto - Brazil

• Tipo de documento: Artigo Científico
• Fonte: AMERICAN JOURNAL OF NEPHROLOGY; v. 31, n. 6, p. 527-533, 2010.
• Citações Web of Science: 7

Resumo

Background: Tacrolimus (FK) is currently widely used in transplant immunosuppression and the treatment of autoimmune diseases. However, FK induces nephrotoxicity which is characterized by functional and structural renal injury. The ubiquitous protein annexin A1 (ANXA1) has potent anti-inflammatory effects and protects against ischemia/reperfusion injury. We investigated the effects of exogenous ANXA1 treatment in an experimental model of acute FK nephrotoxicity. Methods: Munich-Wistar rats received a low-salt diet for 1 week and were randomized to treatment with ANXA1 (Ac2-26 peptide 0.5 mg/kg/day s.c.), FK (6 mg/kg/day p.o.), association (FK+ANXA1) and vehicles (1 ml/kg/day) for 7 days. Results: FK induced a significant decrease in glomerular filtration rate and renal blood flow, and a significant increase in renal vascular resistance. In addition, FK caused extensive acute tubule-interstitial damage and an increase in anti-inflammatory ANXA1 expression in renal tissue. Exogenous ANXA1 treatment reduced FK-induced tubular dilatation and macrophage infiltration. For the first time, we observed that FK augmented ANXA1 expression in renal tissue. Conclusion: Exogenous ANXA1 treatment partially protected against FK-induced tubular injury and macrophage infiltration, and may be targeted in renal intervention strategies. Copyright (C) 2010 S. Karger AG, Basel (AU)

• Processo FAPESP: 08/01048-9 - Efeitos da administração da proteína antiinflamatória anexina 1 na nefrotoxicidade dos imunossupressores ciclosporina A e tacrolimus
• Beneficiário: Leandro Pires Araujo
• Modalidade de apoio: Bolsas no Brasil - Mestrado